FibroGen, Inc. (FGEN)

As mentioned, added to this morning. After FGEN good results, Pfizer's acquisition and a stability in biotech -- adding to long.

I have been accumulating a position in SPDR S&P Biotech ETF .   Pfizer's proposed acquisition for Biohaven Pharmaceutical (+73% in after hours) may help the effort today.   I plan to add to XBI and FibroGen today (good results).

More on FibroGen - Roxadustat vs. Erythropoietin (A Comparison of Efficacy in Reversing Ventricular Remodeling in Dialysis Patients with Anemia).

By now you know my theory of considering trading long rentals in stocks that are green in a sea of red.  Here are today's "green candidates" - not a political statement - which are displayed on my stock monitor:   Shockingly, I own three of the four...

More FibroGen data.

FibroGen is down only small after the EPS release and despite the broad market selloff.  The company noted in their 10K that there is a subset of patients in both iPf and dmd they have reversed fibrosis.  View Chart » View in New Window » In first i...

After going through the FibroGen  EPS release, there is no change in my view that the company is an interesting speculative biotech idea. More later.

In the interest in transparency, here is a list of positions I have mentioned in my Diary that I am either long or short. Note: This is not a full list of my portfolio's holdings: Longs: , , , , , , , , , , , , , , , .  Shorts: calls, calls and puts...

On Wednesday Subscriber MFrank delivered a thoughtful (deep) dive on FibroGen .  As I read it I was blown away by MFrank's knowledge base on FibroGen and its products. I hope the depth of my responses elicits a similar reaction!  His comprehensive r...

Here are my previously mentioned longs: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , and .

I haven't mentioned FibroGen in a few weeks - I have been adding on any dip.  This is an important finding that Roxa improves left ventricle function of the heart where Epo does not.  I suspect the FDA has given FGEN a path forward on Rica. It all c...

* It is time for action, not inaction * Volatility brings opportunity   I was very active Thursday afternoon:   Short Covers - Robinhood , Royal Caribbean , Carnival , Morgan Stanley , C3.ai , Bank of America (partial), Wells Fargo (partial), Delta ...

I'm doing a lot of trading this morning. I'm selling short March $454 SDPR S&P 500 calls at $11.35 I sold some more JPMorgan Chase at $156.54 I'm adding to KKR and Blackstone shorts on the morning gap. Oh, and FibroGen is on the move.

I have added to the following longs in the last 30 minutes: , , and . I have also taken in some of my short March put position - on the ramp to day's highs - getting more short exposure on strength.

I continue to get good data points on my speculative biotech, FibroGen .

- Buying more and . - Reloaded on Twitter under $37.50.

FibroGen just doesn't want to decline.

* I have covered my short at $467.41. * I covered my short at $157.94. * Broad-based increase in my and individual cannabis names. * Added to at $30.36. * Added to  at $59.90. * Bidding for more under the market.

According to industry sources, FibroGen is increasing its production capacity for Roxadustat from 4000kg to 5700 kg per year.  FGEN is now a top 10 holding in the ETF.

Here's a surprise. FibroGen is now the sixth largest holdings in the ETF!

FibroGen's getting jiggy.

Adding to at $12.15 now.

* What's to like? Very little.. * Though the averages have held up (thank you "Nifty Seven"), a look under the hood reveals a dismal picture of broken stocks and charts  "Last thing I remember, I was Running for the door I had to find the passage ba...

I have added to AdvisorShares Pure US Cannabis ETF , ViacomCBS and FibroGen this morning.    

FibroGen appeared in two conferences last week.   To summarize the opportunity in China -- there are currently 700k dialysis patients (this is growing 10% a year).   There are an estimated 120 million Chinese citizens with chronic kidney disease (CK...

Biotech is not my area of expertise, so I am trying to throw out as much data as possible on FibroGen in order for subscribers to evaluate the merits of this particular speculative, biotech investment. I don't want to suggest by all the FGEN informa...

Today FibroGen appears at the Jeffries London Healthcare Conference.

I added to the following longs this morning: , , , , and . __________  Long C, IVZ, VIAC common and calls, FGEN, MSOS, DISCK. Short C calls, IVZ calls, VIAC puts, FGEN calls, MSOS calls, DISCK calls.